Pfizer Drops Out Of Indiplon Development; Neurocrine To Seek New Partner

Neurocrine will seek a new commercialization partner for the insomnia agent indiplon following Pfizer's decision to exit a collaboration for the drug, CEO Gary Lyons said during a June 22 conference call